Park Jung-Wee, Yoo Je-Hyun, Lee Young-Kyun, Park Jong-Seok, Won Ye-Yeon
Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Orthopedic Surgery, Hallym University Sacred Heart Hospital, Anyang, Korea.
Hip Pelvis. 2024 Mar 1;36(1):62-69. doi: 10.5371/hp.2024.36.1.62.
To assess current practice in the treatment of osteoporosis in patients who underwent treatment for hip fracture in South Korea.
A survey of 97 members of the Korean Hip Society, orthopedic hip surgeons who administer treatment for hip fractures in South Korea, was conducted. The survey was conducted for assessment of demographic data and perceptions regarding the management of osteoporosis in patients who have undergone treatment for hip fracture. Analysis of the data was performed using descriptive statistical methods.
The majority of participants were between the age of 41 and 50 years, and 74% were practicing in tertiary hospitals. Testing for serum vitamin D levels (82%) was the most commonly performed laboratory test. Calcium and vitamin D were prescribed for more than 80% of patients by 47% and 52% of participants, respectively. Denosumab was the most commonly used first-line treatment option for osteoporosis in hip fracture patients. Bisphosphonate was most often perceived as the cause of atypical femoral fractures, and the most appropriate time for reoperation was postoperative 12 months. Teriparatide was most preferred after cessation of bisphosphonate and only prescribing calcium and vitamin D was most common in high-risk patients for prevention of atypical femoral fracture.
The results of this study that surveyed orthopedic hip surgeons showed that most participants followed the current strategy for management of osteoporosis. Because the end result of osteoporosis is a bone fracture, active involvement of orthopedic surgeons is important in treating this condition.
评估韩国接受髋部骨折治疗的骨质疏松症患者的当前治疗实践。
对韩国髋部协会的97名成员进行了调查，这些成员是在韩国从事髋部骨折治疗的骨科髋部外科医生。该调查旨在评估人口统计学数据以及对接受髋部骨折治疗患者骨质疏松症管理的看法。使用描述性统计方法对数据进行分析。
大多数参与者年龄在41至50岁之间，74% 在三级医院执业。血清维生素D水平检测（82%）是最常进行的实验室检查。分别有47% 和52% 的参与者为超过80% 的患者开具了钙和维生素D。地诺单抗是髋部骨折患者骨质疏松症最常用的一线治疗选择。双膦酸盐最常被认为是非典型股骨骨折的原因，再次手术的最合适时间是术后12个月。在停用双膦酸盐后，特立帕肽最受青睐，在高危患者中仅开具钙和维生素D是预防非典型股骨骨折最常见的做法。
这项对骨科髋部外科医生进行调查的研究结果表明，大多数参与者遵循当前骨质疏松症的管理策略。由于骨质疏松症的最终结果是骨折，骨科医生的积极参与对治疗这种疾病很重要。
